Reference, not advice. Victoza and Saxenda are prescription medicines. This page describes what the evidence shows. It publishes no doses, gives no guidance on use, and does not replace a prescriber. Vallydia does not sell, supply or link to any GLP-1 medicine.
Victoza and Saxenda look like two drugs, but they contain the same molecule – liraglutide, a once-daily GLP-1 receptor agonist. The two boxes differ in what the regulator approved them for, and so in the dose range. The molecule is identical in both.
People usually ask "which one is better?" That's the wrong question. The useful one is "which condition was each trial designed to measure?"
A common online assumption is that Saxenda is a newer or stronger drug and Victoza is the old one. Neither is true. The molecule is the same and so is the mechanism. The higher dose range used for weight management is what the obesity trials tested, and that is the whole difference.
Grades below come from our liraglutide register entry. They are graded per outcome, not per brand.
| Outcome | Grade | Which box it belongs to | What was measured |
|---|---|---|---|
| Glycaemic control in type 2 diabetes | A | Victoza | The LEAD trial programme |
| Weight management in obesity | A | Saxenda | SCALE: roughly 8.4% mean weight loss at 56 weeks |
| Cardiovascular risk | A | Victoza | LEADER (n = 9,340): 13% relative reduction in major cardiovascular events – in people with type 2 diabetes and established cardiovascular disease |
| Adolescent use | A | Saxenda | Kelly et al. 2020, adolescent obesity trial |
Two details matter more than the grades themselves.
The cardiovascular result does not travel. LEADER enrolled people with type 2 diabetes and cardiovascular disease, and the 13% figure belongs to that population. It is not evidence of heart protection in people taking liraglutide for weight alone.
Liraglutide is no longer the strongest option for weight. In the head-to-head STEP 8 trial, liraglutide produced about 6.4% weight loss against about 15.8% for semaglutide. Across trials, mean weight loss is roughly 15% for semaglutide and roughly 22% for tirzepatide. Liraglutide was first in its class, but the newer agents now outperform it on this outcome.
| Victoza | Saxenda | |
|---|---|---|
| Molecule | liraglutide | liraglutide |
| Approved for | Type 2 diabetes (glycaemic control) | Chronic weight management |
| Dose range | Lower | Higher |
| Dosing frequency | Once daily (half-life ~13 h) | Once daily (half-life ~13 h) |
| Key trial | LEAD, LEADER | SCALE, Kelly 2020 |
| Safety profile | Shared – see below | Shared – see below |
The safety signals belong to liraglutide, not to the brand:
Generic liraglutide is now approved. A generic contains the same molecule, so the evidence above applies to it equally. The grades rest on the molecule, not on the manufacturer.
Are Victoza and Saxenda the same drug? Yes. They have the same active molecule, liraglutide. They differ in approved condition and dose range.
Is Saxenda stronger than Victoza? It is the same drug used at a higher dose range. That range is what was tested in the weight-management trials.
Does liraglutide protect the heart? In people with type 2 diabetes and established cardiovascular disease, LEADER showed a 13% relative reduction in major cardiovascular events. That result has not been shown for weight-management use alone.
How does liraglutide compare with semaglutide? For weight, semaglutide produced more than twice the loss in the head-to-head STEP 8 trial: about 15.8% against 6.4%.
Does Vallydia publish doses? No. Dosing is a prescriber's decision.
Victoza and Saxenda don't compete with each other. They are one evidence base split by indication. Victoza carries the diabetes and cardiovascular outcomes. Saxenda carries the weight outcomes, which newer molecules have since overtaken.
Two boxes, one molecule. What differs is which question each trial asked.
Vallydia does not sell, supply or link to any GLP-1 medicine.
How we separate evidence levels: how we grade · how we grade.
Vallydia sells its own cosmetic serums, and some ingredients discussed here belong to the same categories as those products. Assessments are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Brand and trade names appearing in these articles are the property of their respective owners and are used only to identify the product or ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor. Where we judge a claim, we are judging the published evidence for that claim — not making a statement about the company that makes it.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.